Crinetics Pharmaceuticals, Inc. 4

Insider Stephanie Okey had all of her Crinetics Pharmaceuticals, Inc. common shares, RSUs, and multiple tranches of vested stock options canceled and cashed out at the $85.00-per-share merger price in connection with Vertex’s acquisition.

On September 1, 2026, in connection with the closing of Vertex Pharmaceuticals’ acquisition of Crinetics Pharmaceuticals, Inc., all of Stephanie Okey’s equity in Crinetics was canceled and cashed out. Each outstanding share of Crinetics common stock, including shares underlying previously granted restricted stock units, was converted into the right to receive $85.00 in cash, resulting in 6,400 RSU-based shares and a separate 5,925-share position being canceled for cash consideration. In addition, multiple tranches of vested stock options with exercise prices below $85.00 were canceled and converted into cash equal to the spread between the $85.00 merger price and their respective strike prices, covering option blocks of 25,000 shares at a $24.15 strike, 12,500 shares at $23.23, 17,500 shares at $20.23, 17,500 shares at $20.32, 12,500 shares at $44.71, 10,350 shares at $32.33, and 9,730 shares at $35.87. After these merger-driven cancellations and cash-outs, Okey no longer held any Crinetics common stock or options, as the company became a wholly owned subsidiary of Vertex.

Filing Facts

CIK

1658247

Ticker

CRNX

Form

4

Source Type

fda

Accession

0001628280-26-059905

Alert Tier

5